Intellectual Property India Publishes Patent Application for Double-Stranded Rnai Agents And Compositions For Reducing Expression Of Angiopoietin-Like 3 (angptl3) And Methods Of Use Thereof

MUMBAI, India, Sept. 22 -- Intellectual Property India has published a patent application (202647107490 A) filed by Astrazeneca Ab; and Silence Therapeutics Gmbh on September 07, 2026, for Double-Stranded Rnai Agents And Compositions For Reducing Expression Of Angiopoietin-Like 3 (angptl3) And Methods Of Use Thereof.

Inventors include Foinquinos, Ariana; Hurt-Camejo, Eva; Peng, Xiao-Rong; Morrison, Eliot; Giannakopoulos, Stavros; Dames, Sibylle; Johannssen, Timo; Bethge, Lucas; Schubert, Steffen; and Wikstrm Lindholm, Marie.

The application for the patent was published on September 18, 2026, under issue no. 38/2026.

Abstract: There are disclosed certain double-stranded RNA (dsRNA) or siRNA agents for inhibition of angiopoietin-like 3 gen...